Kelsey E. Huntington

This study shows that combining ONC201 with ATR inhibitor ceralasertib synergistically kills ovarian cancer cells by inducing apoptosis and reducing anti-apoptotic proteins.

This study identifies a 12-gene BTB signature, shows CDH5 as a core component, and demonstrates that BIA disrupts the BTB to enhance chemotherapy delivery and efficacy in GBM.

This study shows that combining TLY012 with PD-1 inhibition reduces PDAC tumor growth in mice by enhancing proinflammatory cytokines and immune cell infiltration.

This study shows that combining ONC201 with enzalutamide or darolutamide synergistically reduces mCRPC cell viability and PSA levels, with in vivo anti-tumor effects.

This study investigates how senescent fibroblasts influence tumor growth and immune response, showing that targeting the p21-driven SASP and combining senolytics with cancer therapies can suppress tumor growth.

This study shows that androgen receptor inhibitors enhance NK cell-mediated killing of prostate cancer cells and sensitivity to NKG2A checkpoint blockade by upregulating HLA-E expression.

This study shows that combining lurbinectedin with irinotecan and 5-FU significantly enhances the killing of pancreatic cancer cells.